Metadata Search Funding Data Link References Status API Help
Facet browsing currently unavailable
Page 3 of 57328 results
Sort by: relevance publication year
Showing results for ISSN matching 0923-7534

1711P Spatial transcriptomics reveals substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications

JOURNAL ARTICLE published September 2022 in Annals of Oncology

Authors: X. Wang | D. Venet | F. Lifrange | D. Larsimont | M. Rediti | L. Stenbeck | D. Gacquer | F. Dupont | G. Rouas | M. Serra | J. Lundeberg | F. Rothé | C. Sotiriou

https://doi.org/10.1016/j.annonc.2022.07.1789 Actions

LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation

JOURNAL ARTICLE published September 2022 in Annals of Oncology

Authors: P.A. Ascierto | M. Mandala | P.F. Ferrucci | M. Guidoboni | P. Rutkowski | V. Ferraresi | A.M. Arance Fernandez | M. Guida | E. Maiello | H.J. Gogas | E. Richtig | M.T. Fierro | C. Lebbe | H. Helgadottir | I. Melero | G. Palmieri | D. Giannarelli | A.M. Grimaldi | R. Dummer | V. Chiarion Sileni

https://doi.org/10.1016/j.annonc.2022.08.040 Actions

1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: S.M. Yip | K. Fizazi | N. Matsubara | A.A. Azad | J.Y. Joung | P.C. Fong | J. Carles Galceran | U.F.F. De Giorgi | R.J. Jones | G. Liu | A.P. Fay | E. Voog | S. Zschäbitz | J. Oldenburg | N. Di Santo | C.G. Healy | X. Lin | D. Laird | N. Agarwal

https://doi.org/10.1016/j.annonc.2023.09.2760 Actions

1324MO CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: R.A. Soo | B.C. Cho | J-H. Kim | M-J. Ahn | K.H. Lee | A. Zimina | S. Orlov | I. Bondarenko | Y-G. Lee | L. Yueh Ni | S.S. Lee | K.H. Lee | Y.K. Pang | C.H. Fong | J.H. Kang | C.S. Lim | P. Danchaivijitr | H. Lee | S. Park | I. Cicin

https://doi.org/10.1016/j.annonc.2023.09.2357 Actions

71P Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: L. Skidmore | D. Mills | J.Y. Kim | K. Tatsukawa | N. Knudsen | J. Nelson | J. Wang | S. Zhang

https://doi.org/10.1016/j.annonc.2023.09.1571 Actions

1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: S. Babu | S. Kondo | N. Ammakkanavar | A.I. Spira | R. Perets | T. Doi | J. Bar | A. Vandross | D. Sommerhalder | V. Nikolic | C. Tribouley | H. Atluri | J. Hong | A. Paustian | R. Leibman | J. Powderly

https://doi.org/10.1016/j.annonc.2023.09.2973 Actions

475P Dynamics of TROP2 expression in triple-negative breast cancer

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: A.C. Garrido-Castro | J. Gomez Tejeda Zanudo | J. Navarro | A.M. Barkell | A. Frangieh | A. Mohammed-Abreu | M.E. Hughes | B. Binboga Kurt | R.J. Hill | T.A. King | E.A. Mittendorf | M.C. Rebelatto | D. Carroll | N.U. Lin | S.M. Tolaney | E.C. De Bruin

https://doi.org/10.1016/j.annonc.2023.09.651 Actions

1652P Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: R. Ruzi | J. Song | Y. Chen | R. Xu | X. Yin | Q. Xu | C. Wang | Y. Zhao

https://doi.org/10.1016/j.annonc.2023.09.2601 Actions

1906P Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: A. Hartmann | L. Vorfelder | M. Ahrens | J.B.A.G. Haanen | B. Escudier | A. Ravaud | E. Boleti | G. Gravis | A. Flechon | M-O. Grimm | J. Bedke | B. Mellado Gonzalez | P. Ivanyi | I. Polifka | F. Lange | A. Agaimy | L. Bergmann | C.G. Stöhr

https://doi.org/10.1016/j.annonc.2023.09.1136 Actions

1896P Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: T.R. Geldart | L.M. Pickering | A. Sharma | D. Scott | O.A. Parikh | P. Dhokia | M. Hale | L. Vaz

https://doi.org/10.1016/j.annonc.2023.09.1126 Actions

1993P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: M.D. Isla Casado | E. Arriola | M.R. García-Campelo | P. Diz Tain | C. Marti Blanco | M.M. Lopez-Brea Piqueras | A.L. Moreno Vega | L.A. Leon Mateos | J.M. Oramas Rodriguez | V. Gutierrez Calderon | M. Majem | A. Sanchez Hernandez | C. Aguado | R. Alvarez Cabellos | J.L. Marti Ciriquian | A. Moreno Paul | J.L. Firvida Perez | Á. Callejo Mellén | L. Baez | L. Paz-Ares

https://doi.org/10.1016/j.annonc.2023.09.1224 Actions

423P A real-world study on the clinical value of apatinib-based regimens in metastatic triple-negative breast cancer

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: H.W. Wei | C. Qi | W. Xi | H. Jian | L. Jian | W. Li | W. Fan | X. Chen | L. Ni | H. Yi

https://doi.org/10.1016/j.annonc.2023.09.599 Actions

P-129 Necessity and safety of simultaneous cholecystectomy during gastric surgery in patients with asymptomatic cholelithiasis: A systematic review and meta-analysis

JOURNAL ARTICLE published June 2023 in Annals of Oncology

Research funded by Health and Family Planning Commission of Sichuan Province (20ZD007)

Authors: T. Jiang | H. Zhang | X. Yin | Z. Cai | Z. Zhao | M. Mu | B. Liu | C. Shen | B. Zhang | Y. Yin

https://doi.org/10.1016/j.annonc.2023.04.185 Actions

445TiP VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state

JOURNAL ARTICLE published September 2022 in Annals of Oncology

Authors: A. Pastorino | A. Puccini | V. Martelli | M. Grassi | M. Cremante | A. Gandini | S. Puglisi | F. Catalano | V. Murianni | A. Pessino | V. Andretta | S. Mammoliti | M.S. Sciallero | D. Comandini | G. Fornarini | F. Caprioni | G. Bregni | S. Barni | R. Labianca | A.F. Sobrero

https://doi.org/10.1016/j.annonc.2022.07.1866 Actions

302P Treatment patterns in resectable early-stage NSCLC in Taiwan: Subgroup analysis of a global real-world study

JOURNAL ARTICLE published November 2022 in Annals of Oncology

Authors: J-Y. Shih | S.H. Lin | S. Nagar | M. Jimenez | K. Davis | D. Kahangire | L. Servidio | L. Ho | R. Veluswamy

https://doi.org/10.1016/j.annonc.2022.10.330 Actions

PD-10 Organoids as tools for functional precision oncology in advanced pancreatic cancer

JOURNAL ARTICLE published June 2023 in Annals of Oncology

Authors: A. Boileve | N. Goudarzi | J. Cartry | S. Bedja | J. Mathieu | A. Mouawia | C. Nicotra | M. Ngo-Camus | K. Lipson | V. Boige | D. Malka | M. Valéry | A. Tarabay | M. Bani | P. Dartigues | T. De Baere | A. Italiano | M. Gelli | C. Smolenschi | M. Ducreux | A. Hollebecque | F. Jaulin

https://doi.org/10.1016/j.annonc.2023.04.037 Actions

P-111 PD1 and LAG3 inhibition as second+ line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer

JOURNAL ARTICLE published June 2023 in Annals of Oncology

Authors: J. Mencel | F. Turkes | L. Barber | B. Challoner | M. Buzzetti | A. Tran | H. Chen | N. McCafferty | A. Woolston | R. Crux | I. Rana | J. Thomas | V. Borja | R. Begum | E. Johnston | N. Fotiadis | M. Terlizzo | S. Rao | I. Chau | D. Cunningham | M. Gerlinger | N. Starling

https://doi.org/10.1016/j.annonc.2023.04.167 Actions

P-154 Using the EVendo score to predict varices and varices needing treatment in hepatocellular carcinoma patients planned for atezolizumab-bevacizumab

JOURNAL ARTICLE published June 2023 in Annals of Oncology

Authors: C. Toh | J. Jie Xin Lee | D. Tai | S. Lee

https://doi.org/10.1016/j.annonc.2023.04.210 Actions

P-56 Brightline-2: A phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours

JOURNAL ARTICLE published June 2023 in Annals of Oncology

Authors: T. Macarulla | J. Harding | C. Morizane | K. Ohkawa | M. Ueno | A. Vogel | A. Lamarca | N. Yamamoto | M. Javle | J. Hu | M. Teufel | A. Märten | L. Goyal | C. Yoo

https://doi.org/10.1016/j.annonc.2023.04.112 Actions

P-404 Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape – RT) – results of a large cohort study

JOURNAL ARTICLE published June 2023 in Annals of Oncology

Authors: M. Reddy Yallala | A. Shah | V. Ostwal | A. Saklani | M. Kazi | R. Engineer | P. Bhargava | S. Srinivas | A. Ramaswamy | S. Ankathi | A. Baheti

https://doi.org/10.1016/j.annonc.2023.04.460 Actions
Feedback: support@crossref.org